NCT01029795终止2 期
A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks
研究概览
简要总结
The purpose of this study is to help answer the following research question(s):
- To test if taking LY2599506 for 12 weeks controls blood sugar better than taking glyburide for 12 weeks.
- To evaluate the safety of LY2599506 in participants with diabetes.
- To determine if LY2599506 has the ability to control blood sugar in participants with diabetes.
- To determine how much LY2599506 should be given to participants.
- To determine if LY2599506 has an effect on a participant's weight.
The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have type 2 diabetes mellitus prior to entering the trial
- •Are currently being treated with diet and exercise therapy consistent with the local standards of medical care
- •Treated with: Diet and exercise alone; or Diet and exercise in combination with a stable dose of metformin for at least 3 months prior to entering the trial; or Diet and exercise in combination with a stable dose of sulfonylurea for at least 3 months prior to entering the trial; or Diet and exercise in combination with stable doses of metformin and sulfonylurea for at least 3 months prior to entering the trial and have had diabetes for at least 6 years.
- •Have an HbA1c value between 7% and 10%
- •Are women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. Male patients will be advised to use a reliable method of birth control during the study and until 3 months after the last dose of study medication if their partner is of child-bearing potential.
排除标准
- •Use of insulin or any antidiabetic agent other than metformin or sulfonylurea during the 3 months prior to entering the trial.
- •Have a gastrointestinal disease that significantly impacts gastric emptying or motility (for example, severe gastroparesis or pyloric stenosis), in the opinion of the Investigator, or have undergone gastric bypass or gastric banding surgery.
- •Have had more than 1 episode of severe hypoglycemia within 6 months prior to entry into the study, or are currently diagnosed as having hypoglycemia unawareness
- •Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months.
- •Have cardiac autonomic neuropathy (for example, resting tachycardia or orthostatic hypotension), based on clinical signs, symptoms, or appropriate diagnostic testing.
- •Have cardiac disease with functional status that is New York Heart Association Class II, III, or IV or a history of myocardial infarction, unstable angina, or decompensated congestive heart failure in the past 6 months.
- •Have poorly controlled hypertension (that is, mean systolic blood pressure >160 mm Hg or mean diastolic blood pressure >100 mm Hg) history of malignant hypertension, evidence of renal artery stenosis, and/or evidence of labile blood pressure including symptomatic postural hypotension. Doses of antihypertensive medications must be stable for 30 days before randomization.
- •Have fed or fasting state hypertriglyceridemia (defined as >6.8 millimoles per liter [mmol/L], 600 milligrams per deciliter [mg/dL]) at screening. If taking lipid-lowering agents, doses of these medications must be stable for 30 days prior to randomization.
- •Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or repeated alanine transaminase (ALT) levels >2.5 times the upper limit of the reference range at screening.
- •Have evidence of a significant active, uncontrolled endocrine or autoimmune abnormality, as judged by the Investigator at screening.
- •Have an active or untreated malignancy or have been in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
- •Have a history of seizure disorder.
研究组 & 干预措施
LY2599506
Experimental
Combinations of 50-milligram (mg) or 100-mg capsules of LY2599506 or matching placebo capsules (each dose contains at least 1 capsule of active drug). LY2599506 will be administered, based on predefined glycemic targets, in escalating doses from 100 mg/day up to 800 mg/day.
干预措施: LY2599506 (Drug)
LY2599506
Experimental
Combinations of 50-milligram (mg) or 100-mg capsules of LY2599506 or matching placebo capsules (each dose contains at least 1 capsule of active drug). LY2599506 will be administered, based on predefined glycemic targets, in escalating doses from 100 mg/day up to 800 mg/day.
干预措施: Placebo (Drug)
Glyburide
Active Comparator
Combinations of 2.5-mg capsules of Glyburide or matching placebo capsules (each dose contains at least 1 capsule of active drug). Glyburide will be administered, based on predefined glycemic targets, in escalating doses from 5 mg/day up to 20 mg/day.
干预措施: Glyburide (Drug)
Glyburide
Active Comparator
Combinations of 2.5-mg capsules of Glyburide or matching placebo capsules (each dose contains at least 1 capsule of active drug). Glyburide will be administered, based on predefined glycemic targets, in escalating doses from 5 mg/day up to 20 mg/day.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks
时间窗: Baseline, 12 weeks
Change in HbA1c from baseline following 12 weeks of therapy (HbA1c at week 12 minus HbA1c at baseline). Study GMAJ was terminated after enrolling 38 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
次要结局
- Change From Baseline in the European Quality of Life -5 Dimension (EQ-5D) at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Change From Baseline in the Homeostasis Model Assessment (HOMA2) Pancreatic Beta Cell Function (%B) at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Change From Baseline in the QT Interval in Electrocardiogram (ECG) at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Change From Baseline in the Adult Low Blood Sugar Survey (LBSS-33 Item Scale) at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Maximum Plasma Concentration (Cmax) at the Steady State for LY2599506(Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12)
- 30-day Adjusted Rates of Self-reported Hypoglycemic Episodes Overall(Baseline through 16 weeks)
- Change From Baseline in Heart Rate at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Mean Morning Dose of LY2599506 During the 12-week Treatment Period(Baseline, 1, 2, 3, 4, 6, 8, 10, 12 weeks.)
- Change From Baseline in the Homeostasis Model Assessment (HOMA2) of Insulin Sensitivity (%S) at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Change From Baseline in Triglycerides, Low-density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, Total Cholesterol, and Free Fatty Acids at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Change From Baseline in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Change From Baseline in the Perceptions About Medications - Diabetes (PAM-D) Questionnaire at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Changes From Baseline in the Diabetes Symptoms Checklist-Revised (DSC-R) at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Number of Hypoglycemic Episodes During 12-week Treatment Period and 4-week Follow-up Period(Baseline through 16 weeks)
- Change From Baseline in Body Weight at 12 Weeks and 16 Weeks(Baseline, 12 weeks, 16 weeks)
- Change From Baseline in the Seven-Point Self-Monitored Blood Glucose (7-point SMBG) at 4 Weeks, 12 Weeks, and 16 Weeks(Baseline, 4 weeks, 12 weeks, 16 weeks)
- Percentage of Participants With Lipase and Amylase Measurements Above 2-fold Upper Limits of Normal (ULN) During the 12-week Treatment Period(Baseline through 12 weeks)
- Percentage of Participants With Clinically-Significant Elevations of Alanine Aminotransferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT) During the 12-week Treatment Period(Baseline through 12 weeks)
- Area Under the Concentration-Time Curve (AUC) at a Dosing Interval (AUCtau) at the Steady State for LY2599506(Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12)
- Mean Afternoon Dose of LY2599506 During the 12-week Treatment Period(Baseline, 1, 2, 3, 4, 6, 8, 10, 12 weeks.)
- Percentage of Participants Requiring Dose Adjustments During the 12-week Treatment Period(Baseline through 12 weeks)
- Mean Total Daily Dose of LY2599506 During the 12-week Treatment Period(Baseline through 12 weeks.)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Study of LY2599506 in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01024244Eli Lilly and Company78
已完成
2 期
A Study in Advanced Solid TumorsSolid TumorNCT01063075Eli Lilly and Company34
已完成
2 期
Study in Advanced Solid TumorsSolid TumorNCT01099358Eli Lilly and Company47
Unknown
1 期
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian CancerMalignant Female Reproductive System NeoplasmCancerOvarian CancerOvarian Epithelial Cancer RecurrentOvarian TumorNCT01715168Azaya Therapeutics, Inc.40
已完成
2 期
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast CancerBreast CancerNCT00451555Eli Lilly and Company156